Simvastatin Enhances Activity and Trafficking of α7 Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways.

Tingting Chen,Baofeng Zhang,Lei Chen,Ling Chen,Ya Wang,Liandong Zhao,Tingting Zhang

doi:10.3389/fphar.2018.00362

Tingting Chen, Baofeng Zhang + Show 5 more

Open Access

https://doi.org/10.3389/fphar.2018.00362

Copy DOI

Abstract

Simvastatin (SV) enhances glutamate release and synaptic plasticity in hippocampal CA1 region upon activation of α7 nicotinic acetylcholine receptor (α7nAChR). In this study, we examined the effects of SV on the functional activity of α7nAChR on CA1 pyramidal cells using patch-clamp recording and explored the underlying mechanisms. We found that the treatment of hippocampal slices with SV for 2 h induced a dose-dependent increase in the amplitude of ACh-evoked inward currents (IACh) and the level of α7nAChR protein on the cell membrane without change in the level of α7nAChR phosphorylation. These SV-induced phenotypes were suppressed by addition of farnesol (FOH) that converts farnesyl pyrophosphate, but not geranylgeraniol. Similarly, the farnesyl transferase inhibitor FTI277 was able to increase the amplitude of IACh and enhance the trafficking of α7nAChR. The treatment with SV enhanced phosphorylation of CaMKII and PKC. The SV-enhanced phosphorylation of CaMKII rather than PKC was blocked by FOH, Src inhibitor PP2 or NMDA receptor antagonist MK801 and mimicked by FTI. The SV-enhanced phosphorylation of PKC was sensitive to the IP3R antagonist 2-APB. The SV-increased amplitude of IACh was suppressed by PKC inhibitor GF109203X and Go6983, or CaMKII inhibitor KN93. The SV- and FTI-enhanced trafficking of α7nAChR was sensitive to KN93, but not GF109203X or Go6983. The PKC activator PMA increased α7nAChR activity, but had no effect on trafficking of α7nAChR. Collectively, these results indicate that acute treatment with SV enhances the activity and trafficking of α7nAChR by increasing PKC phosphorylation and reducing farnesyl-pyrophosphate to trigger NMDA receptor-mediated CaMKII activation.

Highlights

Statins, which are inhibitors of 3-hydroxy-3-methyl-glytarylcoenzyme A (HMA-CoA) reductase, have received much attention due to the lower prevalence of Alzheimer’s disease (AD) and/or dementia in patients treated with these drugs (Wolozin et al, 2000)
The findings suggest that the SV treatment did not alter the affinity of α7 nicotinic acetylcholine receptor (α7nAChR). (4) The phosphorylation status of α7nAChR was not altered by treatment with SV
FPP is essential for the Ras farnesylation, a process catalyzed by prenyltransferase farnesyl transferase (Kho et al, 2004)

Summary

Introduction

Statins, which are inhibitors of 3-hydroxy-3-methyl-glytarylcoenzyme A (HMA-CoA) reductase, have received much attention due to the lower prevalence of Alzheimer’s disease (AD) and/or dementia in patients treated with these drugs (Wolozin et al, 2000). SV-Potentiated α7nAChR Activity functions in normal cholesterolemic AD patients (Simons et al, 2002). Treatment with SV can improve cognition in AD patients through a mechanism unrelated to its cholesterol-lowering effects (Jick et al, 2000). The decline of α7nAChR level and dysfunction of α7nAChR have been found in the brains of AD patients (Burghaus et al, 2000; Kihara et al, 2004). One important characteristic of α7nAChR is its high permeability to Ca2+, α7nAChR plays an important role in synaptic plasticity and cognitive function (Sharma and Vijayaraghavan, 2003; Chen et al, 2016a). The dysfunction of α7nAChR is known to be critical pathogenic process and mechanism of cognitive disorder in AD (Chen et al, 2006). The chronic administration of SV in mice enhances the presynaptic glutamate release and facilitates the hippocampal long-term potentiation induction via the activation of α7nAChR (Chen et al, 2016a)

Methods

Results

Conclusion